WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has unveiled new data on istaroxime, a treatment candidate for cardiogenic shock, at the European Society of Cardiology Heart Failure 2025 Conference in Belgrade, Serbia. The findings, shared in a presentation titled “Safety and Efficacy of up to 60 Hours of Intravenous Istaroxime for Patients with Pre-Cardiogenic Shock: the SEISMiC Trial,” highlight the drug’s potential to improve outcomes for a condition often associated with high mortality and cost of care.
Presented by Dr. Jan Biegus of Wroclaw Medical University, the data stems from the SEISMiC Extension Phase 2b study. The results bolster istaroxime’s prospects as the first dual-mechanism therapy designed to enhance both systolic and diastolic cardiac function in patients with early cardiogenic shock.
“The positive results from the SEISMiC Extension Study are important data to help us advance istaroxime toward Phase 3 for cardiogenic shock,” said Dr. Steve Simonson, Chief Medical Officer and Senior Vice President of Windtree Therapeutics. “We believe that istaroxime is differentiating itself from currently available therapies to support the acutely failing heart. The unique profile of istaroxime is well-suited to potentially be a new important treatment for cardiogenic shock which has high mortality, morbidity and cost of care.”
A Dual-Mechanism Breakthrough
Istaroxime operates through a powerful dual-mechanism approach. By inhibiting Na+/K+-ATPase, it increases myocardial contractility, while simultaneously facilitating myocardial relaxation through activation of the SERCA2a calcium pump. This enhances calcium reuptake in the heart muscles, supporting efficient cardiac function without elevating heart rate or increasing the risk of arrhythmias.
The therapy has demonstrated significant improvements in cardiac function and blood pressure across multiple Phase 2 studies, underscoring its potential to address gaps in current cardiogenic shock treatments.
Path to the Next Phase
With the SEISMiC Extension Phase 2b results reinforcing its therapeutic promise, Windtree plans to progress istaroxime into Phase 3 trials. The company remains focused on developing innovative solutions for cardiovascular conditions, positioning istaroxime as a potential game-changer in managing acute and complex heart failure scenarios.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.